10X Genomics, Inc. (TXG) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

10X Genomics, Inc.

Gilead Sciences, Inc.

Biogen, Inc.

Halozyme Therapeutics, Inc.

Bio-Techne Corp.

Elanco Animal Health, Inc.

Illumina, Inc.

BioMarin Pharmaceutical, Inc.

Moderna, Inc.

Vaxcyte, Inc.

Immunovant, Inc.

Why is 10X Genomics, Inc. ?

The company has declared positive results for the last 5 consecutive quarters

OPERATING CASH FLOW(Y) Highest at USD 127.82 MM
ROCE(HY) Highest at -2.98%
DEBT-EQUITY RATIO (HY) Lowest at -56.3 %

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 195.37%, its profits have risen by 52.3%

High Institutional Holdings at 100%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Market Beating Performance

The stock has generated a return of 195.37% in the last 1 year, much higher than market (S&P 500) returns of 22.24%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to 10X Genomics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is 10X Genomics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

10X Genomics, Inc.

217.72%

0.62

70.12%

S&P 500

20.78%

1.67

13.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

16.55%

EBIT Growth (5y)

-5.44%

EBIT to Interest (avg)

-143.37

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.59

Sales to Capital Employed (avg)

0.83

Tax Ratio

2.37%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.13

EV to EBIT

-18.62

EV to EBITDA

-31.72

EV to Capital Employed

6.96

EV to Sales

3.07

PEG Ratio

Dividend Yield

ROCE (Latest)

-37.38%

ROE (Latest)

-10.80%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

18What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 127.82 MM

ROCE(HY)

Highest at -2.98%

DEBT-EQUITY RATIO (HY)

Lowest at -56.3 %

RAW MATERIAL COST(Y)

Fallen by -0.65% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 11.75 times

PRE-TAX PROFIT(Q)

At USD -12.87 MM has Grown at 69.8%

NET PROFIT(Q)

At USD -13.49 MM has Grown at 68.95%

0What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Here's what is working for 10X Genomics, Inc.

Operating Cash Flow

Highest at USD 127.82 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Debt-Equity Ratio

Lowest at -56.3 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Pre-Tax Profit

At USD -12.87 MM has Grown at 69.8%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

At USD -13.49 MM has Grown at 68.95%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

Debtors Turnover Ratio

Highest at 11.75 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -0.65% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales